Bionano Genomics Stock to Reverse Split on Monday, January 27th (NASDAQ:BNGO)

Bionano Genomics, Inc. (NASDAQ:BNGO)’s stock is scheduled to reverse split on the morning of Monday, January 27th. The 1-60 reverse split was announced on Wednesday, January 22nd. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, January 24th.

Bionano Genomics Stock Down 28.7 %

NASDAQ:BNGO traded down $0.05 during mid-day trading on Thursday, hitting $0.13. 31,894,418 shares of the company’s stock were exchanged, compared to its average volume of 19,639,521. Bionano Genomics has a one year low of $0.13 and a one year high of $1.36. The business has a fifty day moving average price of $0.23 and a 200 day moving average price of $0.37. The company has a market cap of $15.47 million, a PE ratio of -0.06 and a beta of 2.22. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.43 and a quick ratio of 0.99.

Wall Street Analyst Weigh In

Separately, LADENBURG THALM/SH SH cut Bionano Genomics from a “buy” rating to a “neutral” rating in a research report on Friday, November 15th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BNGO. GSA Capital Partners LLP purchased a new stake in shares of Bionano Genomics during the third quarter valued at $46,000. Geode Capital Management LLC raised its position in Bionano Genomics by 47.3% in the 3rd quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock worth $401,000 after buying an additional 283,639 shares during the last quarter. Armistice Capital LLC bought a new position in Bionano Genomics during the 2nd quarter valued at about $1,138,000. Finally, Carret Asset Management LLC boosted its holdings in shares of Bionano Genomics by 89.0% during the 3rd quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock valued at $39,000 after acquiring an additional 40,055 shares during the last quarter. Institutional investors own 11.35% of the company’s stock.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.